TY - JOUR
T1 - Gastrointestinal symptoms predictors of health-related quality of life in pediatric patients with functional gastrointestinal disorders
AU - on behalf of the Pediatric Quality of Life Inventory™ Gastrointestinal Symptoms Module Testing Study Consortium
AU - Varni, James W.
AU - Shulman, Robert J.
AU - Self, Mariella M.
AU - Nurko, Samuel
AU - Saps, Miguel
AU - Saeed, Shehzad A.
AU - Patel, Ashish S.
AU - Dark, Chelsea Vaughan
AU - Bendo, Cristiane B.
AU - Pohl, John F.
AU - Denham, Jolanda
AU - Franciosi, James P.
AU - Neigut, Deborah A.
AU - Nurko, Samuel
AU - Patel, Ashish S.
AU - Pohl, John F.
AU - Saeed, Shehzad
AU - Saps, Miguel
AU - Self, Mariella M.
AU - Shulman, Robert J.
AU - Varni, James W.
AU - Verga, Barbara
AU - Zacur, George M.
N1 - Funding Information:
Item development for the PedsQL™ Gastrointestinal Symptoms Module was previously supported by Takeda Pharmaceuticals North America, Inc. Data collection for the healthy controls sample was supported by intramural funding from the Texas A&M University Foundation.
Funding Information:
Dr. Varni holds the copyright and the trademark for the PedsQL™ and receives financial compensation from the Mapi Research Trust, which is a nonprofit research institute that charges distribution fees to for-profit companies that use the Pediatric Quality of Life Inventory™. Dr. Varni received investigator-initiated funding from Takeda Pharmaceuticals North America, Inc. (Deerfield, Illinois) for the previous item generation qualitative methods study. Dr. Pohl received investigator-initiated funding from Takeda Pharmaceuticals North America, Inc. (Deerfield, Illinois) for the previous item generation qualitative methods study. Drs. Varni and Pohl did not receive funding from Takeda Pharmaceuticals North America, Inc. for the current quantitative methods field test study. Dr. Pohl has received the following funding: INSPPIRE to Study Acute Recurrent and Chronic Pancreatitis is Children, Grant # 10987759, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Pohl is on the speaker’s bureau for Medical Education Resources, Inc. Dr. Shulman is supported by NIH grants R01 NR013497 and T32 DK007664 and receives research funding from Mead-Johnson and is a consultant for Nutrinia. Dr. Nurko is supported by NIH grant K24DK082792A. Dr Saeed is on the speaker’s bureau for Abbvie, Inc. These grants are not related to the current study. The other authors report no competing interests related to this study. Dr. Saps is now at the Division of Digestive Diseases, Hepatology, and Nutrition, Nationwide Children’s Hospital, Ohio State University, Columbus, OH. Dr. Saeed is now at the Division of Pediatric Gastroenterology, Dayton Children’s Hospital, Wright State University, Dayton, OH. Dr. Vaughan Dark is now at the Division of Pediatric Pulmonology, Children’s Medical Center, Dallas, TX.
Publisher Copyright:
© 2016, Springer International Publishing Switzerland.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objectives: To investigate the patient-reported multidimensional gastrointestinal symptoms predictors of generic health-related quality of life (HRQOL) in pediatric patients with functional gastrointestinal disorders (FGIDs). Methods: The Pediatric Quality of Life Inventory™ (PedsQL™) Gastrointestinal Symptoms Scales and PedsQL™ 4.0 Generic Core Scales were completed in a 9-site study by 259 pediatric patients with functional constipation, functional abdominal pain (FAP), or irritable bowel syndrome (IBS). Gastrointestinal Symptoms Scales measuring stomach pain, stomach discomfort when eating, food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea were identified as clinically important symptom differentiators from healthy controls based on prior findings, and subsequently tested for bivariate and multivariate linear associations with overall HRQOL. Results: Gastrointestinal symptoms were differentially associated with decreased HRQOL in bivariate analyses for the three FGIDs. In predictive models utilizing hierarchical multiple regression analyses controlling for age, gender, and race/ethnicity, gastrointestinal symptoms differentially accounted for an additional 47, 40, and 60 % of the variance in patient-reported HRQOL for functional constipation, FAP, and IBS, respectively, reflecting large effect sizes. Significant individual gastrointestinal symptoms predictors were identified after controlling for the other gastrointestinal symptoms in the FGID-specific predictive models. Conclusions: Gastrointestinal symptoms represent potentially modifiable predictors of generic HRQOL in pediatric patients with FGIDs. Identifying the condition-specific gastrointestinal symptoms that are the most important predictors from the patient perspective facilitates a patient-centered approach to targeted interventions designed to ameliorate impaired overall HRQOL.
AB - Objectives: To investigate the patient-reported multidimensional gastrointestinal symptoms predictors of generic health-related quality of life (HRQOL) in pediatric patients with functional gastrointestinal disorders (FGIDs). Methods: The Pediatric Quality of Life Inventory™ (PedsQL™) Gastrointestinal Symptoms Scales and PedsQL™ 4.0 Generic Core Scales were completed in a 9-site study by 259 pediatric patients with functional constipation, functional abdominal pain (FAP), or irritable bowel syndrome (IBS). Gastrointestinal Symptoms Scales measuring stomach pain, stomach discomfort when eating, food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea were identified as clinically important symptom differentiators from healthy controls based on prior findings, and subsequently tested for bivariate and multivariate linear associations with overall HRQOL. Results: Gastrointestinal symptoms were differentially associated with decreased HRQOL in bivariate analyses for the three FGIDs. In predictive models utilizing hierarchical multiple regression analyses controlling for age, gender, and race/ethnicity, gastrointestinal symptoms differentially accounted for an additional 47, 40, and 60 % of the variance in patient-reported HRQOL for functional constipation, FAP, and IBS, respectively, reflecting large effect sizes. Significant individual gastrointestinal symptoms predictors were identified after controlling for the other gastrointestinal symptoms in the FGID-specific predictive models. Conclusions: Gastrointestinal symptoms represent potentially modifiable predictors of generic HRQOL in pediatric patients with FGIDs. Identifying the condition-specific gastrointestinal symptoms that are the most important predictors from the patient perspective facilitates a patient-centered approach to targeted interventions designed to ameliorate impaired overall HRQOL.
KW - Functional abdominal pain
KW - Functional constipation
KW - Gastrointestinal symptoms
KW - Irritable bowel syndrome
KW - Patient-reported outcomes
KW - PedsQL
UR - http://www.scopus.com/inward/record.url?scp=84991269259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991269259&partnerID=8YFLogxK
U2 - 10.1007/s11136-016-1430-3
DO - 10.1007/s11136-016-1430-3
M3 - Article
C2 - 27743332
AN - SCOPUS:84991269259
SN - 0962-9343
VL - 26
SP - 1015
EP - 1025
JO - Quality of Life Research
JF - Quality of Life Research
IS - 4
ER -